Lifecore Biomedical, Inc. \De\ (LFCR): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of LFCR were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Lifecore Biomedical, Inc. \De\
From the latest filingsOverall: more buying than selling. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns LFCR
99 funds and institutions reported LFCR shares worth $134M at the end of Q2 2026, about 68% of the company. The largest holder is Wynnefield Capital Inc with 12.5%.
Funds and institutions (13F) 68%Everyone else 32%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Wynnefield Capital Inc | 4.70M | 12.55% | $24.7M | No change |
| Legion Partners Asset Management, LLC | 4.46M | 11.91% | $23.4M | No change |
| Greenhaven Road Investment Management, L.P. | 3.19M | 8.51% | $16.8M | -10% |
| 325 Capital LLC | 2.90M | 7.73% | $15.2M | +34% |
| BlackRock, Inc. | 2.01M | 5.37% | $10.6M | +7% |
| Vanguard Capital Management LLC | 1.29M | 3.44% | $6.8M | -0% |
| Geode Capital Management, LLC | 855,500 | 2.28% | $4.5M | +5% |
| Morgan Stanley | 769,360 | 2.05% | $4M | +1% |
| State Street Corp | 668,031 | 1.78% | $3.5M | +4% |
| Quinn Opportunity Partners LLC | 453,495 | 1.21% | $2.4M | No change |
| DCF Advisers, LLC | 424,500 | 1.13% | $2.2M | No change |
| Wittenberg Investment Management, Inc. | 314,015 | 0.84% | $1.6M | +4% |
| Northern Trust Corp | 253,817 | 0.68% | $1.3M | +11% |
| Vanguard Fiduciary Trust Co | 239,924 | 0.64% | $1.3M | +1% |
| LPL Financial LLC | 207,300 | 0.55% | $1.1M | -0% |
| Vanguard Portfolio Management LLC | 189,073 | 0.50% | $993K | +15% |
| Marshall Wace, LLP | 177,471 | 0.47% | $932K | +204% |
| Tocqueville Asset Management L.P. | 151,700 | 0.40% | $796K | No change |
| Millennium Management LLC | 133,305 | 0.36% | $700K | -15% |
| Goldman Sachs Group Inc | 124,940 | 0.33% | $656K | -26% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No LFCR insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
LFCR short interest
Low short interest. 4.5% of LFCR shares are sold short: about 1 share in 22. Over the last 12 reports the number of shares short went down 33%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.72M LFCR shares were sold short, 4.5% of the shares outstanding, down 4.5% from the report before. At the average daily volume of 489,149 shares, buying them all back would take about 3.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.72M | 4.54% | -4% | 489,149 | 3.5 |
| Oct 15, 2026 | 1.80M | 4.76% | -27% | 652,062 | 2.8 |
| Sep 30, 2026 | 2.48M | 6.54% | -7% | 605,555 | 4.1 |
| Sep 15, 2026 | 2.67M | 7.05% | +10% | 167,495 | 15.9 |
| Aug 31, 2026 | 2.42M | 6.40% | +0% | 104,477 | 23.2 |
| Aug 14, 2026 | 2.42M | 6.38% | -7% | 139,166 | 17.4 |
| Jul 31, 2026 | 2.61M | 6.88% | +5% | 142,467 | 18.3 |
| Jul 15, 2026 | 2.48M | 6.62% | +4% | 168,844 | 14.7 |
| Jun 30, 2026 | 2.38M | 6.36% | +0% | 304,006 | 7.8 |
| Jun 15, 2026 | 2.37M | 6.34% | +1% | 193,082 | 12.3 |
| May 29, 2026 | 2.35M | 6.28% | -8% | 184,760 | 12.7 |
| May 15, 2026 | 2.56M | 6.84% | -5% | 190,937 | 13.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Lifecore Biomedical, Inc. \De\ company events
Lifecore Biomedical, Inc. \De\ filed 13 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026AnnouncementAs previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. entered into an Agreement and Plan of Merger with Lifecore Inc. and Hazel Merger Sub, Inc. providing for the merger of Merger Sub with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent. Filing
- Nov 4, 2026ResultsReleased financial results. Filing
- Oct 20, 2026AnnouncementAs previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. entered into an Agreement and Plan of Merger with Lifecore Inc. and Hazel Merger Sub, Inc. On October 16, 2026, the Board of Directors of the Company established November 4, 2026, as the record date for a special meeting of… Filing
- Sep 29, 2026AgreementLifecore Biomedical, LLC, a subsidiary of Lifecore Biomedical, Inc., entered into an Amendment No. 3 to Amended and Restated Contract Manufacturing Agreement with Alcon Research, LLC that is effective November 1, 2026. Filing
- Sep 28, 2026AgreementLifecore Biomedical, Inc. entered into an Agreement and Plan of Merger by and among the Company, Lifecore Inc., a Delaware corporation, and Hazel Merger Sub, Inc., a Delaware corporation and a direct wholly owned Subsidiary of Parent. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jul 2, 2026AnnouncementShared information with investors. Filing
- Jun 5, 2026LeadershipLifecore Biomedical, Inc. held its 2026 annual meeting of stockholders. Filing
- May 6, 2026ResultsReleased financial results. Filing
- Mar 16, 2026ResultsReleased financial results. Filing
- Mar 5, 2026VoteSet dates for shareholder nominations. Filing
- Jan 16, 2026LeadershipThe Compensation Committee of the Board of Directors of Lifecore Biomedical, Inc. approved and adopted the Lifecore Biomedical, Inc. Incentive Bonus Plan effective January 14, 2026 for bonus awards granted on or after the Effective Date. Filing
- Nov 17, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Lifecore Biomedical, Inc. \De\ financials
Famous investors that hold LFCR
3 of the 50 well-known investors we track reported holding LFCR in their latest 13F filing. The largest position is Ken Griffin's, worth $1.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 285,190 | $1.9M | 0.0% | +188% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 163,000 | $1.1M | 0.0% | +55% |
| Israel Englander · Millennium Management | Q3 2026 | 62,555 | $412K | 0.0% | -53% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named LFCR in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Greenhaven Road Investment Management, L.P. | 13G/A | 7.6% |
| Nov 16, 2026 | Greenhaven Road Investment Management, L.P. | 13G/A | 7.6% |
Questions about Lifecore Biomedical, Inc. \De\ (LFCR) stock
Who owns the most LFCR stock?
The largest reported owner of Lifecore Biomedical, Inc. \De\ (LFCR) is Wynnefield Capital Inc, with 12.5% of the company. In total, 99 funds and institutions reported holding LFCR at the end of Q2 2026, together about 68% of the shares. See the largest owners.
Are LFCR insiders buying or selling?
No LFCR insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in LFCR?
As of Oct 30, 2026, 1.72M LFCR shares were sold short, 4.5% of the shares outstanding, down 4.5% from the report before. At the average daily volume of 489,149 shares, buying them all back would take about 3.5 trading days (days to cover). See the history.
Which famous investors hold LFCR?
3 of the 50 well-known investors we track reported LFCR in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $1.9M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.